CN102573820A - 包含抗炎共混物的组合物 - Google Patents
包含抗炎共混物的组合物 Download PDFInfo
- Publication number
- CN102573820A CN102573820A CN2010800450450A CN201080045045A CN102573820A CN 102573820 A CN102573820 A CN 102573820A CN 2010800450450 A CN2010800450450 A CN 2010800450450A CN 201080045045 A CN201080045045 A CN 201080045045A CN 102573820 A CN102573820 A CN 102573820A
- Authority
- CN
- China
- Prior art keywords
- extract
- inhibitor
- inflammatory compound
- compositions
- compositions according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 67
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 239000003112 inhibitor Substances 0.000 claims abstract description 47
- 108010057466 NF-kappa B Proteins 0.000 claims description 50
- 102000003945 NF-kappa B Human genes 0.000 claims description 50
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Natural products OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 39
- 239000000284 extract Substances 0.000 claims description 38
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 claims description 26
- 241000628997 Flos Species 0.000 claims description 22
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 22
- 240000002834 Paulownia tomentosa Species 0.000 claims description 18
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 claims description 14
- 235000010678 Paulownia tomentosa Nutrition 0.000 claims description 13
- 244000188472 Ilex paraguariensis Species 0.000 claims description 10
- 235000003368 Ilex paraguariensis Nutrition 0.000 claims description 10
- 235000006236 Paraguay tea Nutrition 0.000 claims description 10
- AVFIYMSJDDGDBQ-UHFFFAOYSA-N Parthenium Chemical compound C1C=C(CCC(C)=O)C(C)CC2OC(=O)C(=C)C21 AVFIYMSJDDGDBQ-UHFFFAOYSA-N 0.000 claims description 8
- 241001495454 Parthenium Species 0.000 claims description 8
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 claims description 7
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 claims description 7
- 241000790646 Cotinis Species 0.000 claims description 6
- 235000011201 Ginkgo Nutrition 0.000 claims description 6
- 244000194101 Ginkgo biloba Species 0.000 claims description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 6
- 241000219991 Lythraceae Species 0.000 claims description 5
- 240000007817 Olea europaea Species 0.000 claims description 5
- 235000002725 Olea europaea Nutrition 0.000 claims description 5
- 244000294611 Punica granatum Species 0.000 claims description 5
- 235000014360 Punica granatum Nutrition 0.000 claims description 5
- 241000320380 Silybum Species 0.000 claims description 5
- 239000010476 amaranth oil Substances 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 229940092665 tea leaf extract Drugs 0.000 claims description 5
- 239000002023 wood Substances 0.000 claims description 5
- 229960001755 resorcinol Drugs 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 31
- 125000001424 substituent group Chemical group 0.000 description 21
- -1 phenol chemical compound Chemical class 0.000 description 17
- 102000004125 Interleukin-1alpha Human genes 0.000 description 15
- 108010082786 Interleukin-1alpha Proteins 0.000 description 15
- 102000004890 Interleukin-8 Human genes 0.000 description 15
- 108090001007 Interleukin-8 Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000003796 beauty Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 206010040954 Skin wrinkling Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003974 emollient agent Substances 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000009759 skin aging Effects 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 241001597008 Nomeidae Species 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000004101 4-Hexylresorcinol Substances 0.000 description 4
- 235000019360 4-hexylresorcinol Nutrition 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 229960003258 hexylresorcinol Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- JPUHXNRAGDKQRD-UHFFFAOYSA-N 4-octylbenzene-1,3-diol Chemical compound CCCCCCCCC1=CC=C(O)C=C1O JPUHXNRAGDKQRD-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 244000192528 Chrysanthemum parthenium Species 0.000 description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 235000008384 feverfew Nutrition 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- FKBGSRCZHMNHGG-UHFFFAOYSA-N 1,4-dimethylazulene Chemical compound CC1=CC=CC=C2C(C)=CC=C21 FKBGSRCZHMNHGG-UHFFFAOYSA-N 0.000 description 2
- SWZVJOLLQTWFCW-UHFFFAOYSA-N 2-chlorobenzene-1,3-diol Chemical class OC1=CC=CC(O)=C1Cl SWZVJOLLQTWFCW-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 244000302151 Myroxylon pereirae Species 0.000 description 2
- 235000014150 Myroxylon pereirae Nutrition 0.000 description 2
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N beta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 2
- 229940069510 parthenolide Drugs 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- RMFFCSRJWUBPBJ-UHFFFAOYSA-N 15-hydroxypentadecyl benzoate Chemical compound OCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 RMFFCSRJWUBPBJ-UHFFFAOYSA-N 0.000 description 1
- IBZJGOGLCABLDJ-UHFFFAOYSA-N 2,4-dinitrosobenzene-1,3-diol Chemical compound OC1=CC=C(N=O)C(O)=C1N=O IBZJGOGLCABLDJ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- GOSCETRPLPACGP-UHFFFAOYSA-N CC1C=CC(O)=CC1O Chemical compound CC1C=CC(O)=CC1O GOSCETRPLPACGP-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FNYDIAAMUCQQDE-UHFFFAOYSA-N Cc(c(O)c1)ccc1O Chemical compound Cc(c(O)c1)ccc1O FNYDIAAMUCQQDE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- DRDRYGIIYOPBBZ-XBXARRHUSA-N Licochalcone B Natural products COC1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1 DRDRYGIIYOPBBZ-XBXARRHUSA-N 0.000 description 1
- WBDNTJSRHDSPSR-UHFFFAOYSA-N Licochalcone C Natural products C1=CC(O)=C(CC=C(C)C)C(OC)=C1C=CC(=O)C1=CC=C(O)C=C1 WBDNTJSRHDSPSR-UHFFFAOYSA-N 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- BIVWQYZTVCQRGV-UHFFFAOYSA-N OC(C1N=O)C(N=O)=CC=C1O Chemical compound OC(C1N=O)C(N=O)=CC=C1O BIVWQYZTVCQRGV-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000001000 anthraquinone dye Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- ONTQJDKFANPPKK-UHFFFAOYSA-L chembl3185981 Chemical compound [Na+].[Na+].CC1=CC(C)=C(S([O-])(=O)=O)C=C1N=NC1=CC(S([O-])(=O)=O)=C(C=CC=C2)C2=C1O ONTQJDKFANPPKK-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- JBBPTUVOZCXCSU-UHFFFAOYSA-L dipotassium;2',4',5',7'-tetrabromo-4,7-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [K+].[K+].O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 JBBPTUVOZCXCSU-UHFFFAOYSA-L 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229930187586 licochalcone Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 description 1
- 229960000850 trioxysalen Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及包含NFκB抑制剂和抗炎化合物的组合物。所述抗炎化合物并非为NFκB抑制剂并且具有约70μg/ml或更低的IC50。
Description
技术领域
本发明提供了包含抗炎化合物的共混物的组合物。该组合物可用于(例如)局部施用至皮肤。
背景技术
抗炎化合物是已知的。本发明人已认识到，存在对识别提供改善性能的抗炎化合物的新组合的需要。
本发明人已发现，称为NFκB抑制剂的抗炎化合物尽管能够降低通过NFκB-通道的免疫应答，但有时促进炎性细胞因子IL-1的释放。本发明人还发现，这些抗炎化合物具有降低通过利用T-细胞受体(TCR)激活剂植物血细胞凝集素刺激的人淋巴细胞产生的细胞因子的强效能力，尤其是具有约70μg/ml或更低的IC50的那些，能够降低免疫应答，但有时趋于促进炎性细胞因子IL-8的释放。
因此，目前已经发现的是，NFκB抑制剂与具有低IC50(尤其是约70μg/ml或更低的IC50)的抗炎化合物的组合提供如下组合物，所述组合物令人吃惊地降低从皮肤和其他组织释放炎性细胞因子IL-1和IL-8，同时还通常提供皮肤和其他组织中的期望的NFκB抑制。
发明内容
在一个方面，本发明提供了包含NFκB抑制剂和抗炎化合物的组合物。当根据本文所述的抗炎检测分析法进行测试时，该抗炎化合物并非为NFκB抑制剂并且具有约70μg/ml或更低的IC50。
根据另一个方面，本发明提供了处理皮肤老化迹象的方法，该方法包括给需要这种处理的皮肤局部施用包含NFκB抑制剂和抗炎化合物的组合物。当根据抗炎检测分析法进行测试时，该抗炎化合物并非为NFκB抑制剂并且具有约70μg/ml或更低的IC50。
通过本发明的具体实施方式和权利要求书，本发明的其他特征和优点将显而易见。
具体实施方式
据信，本领域的技术人员可根据本文的描述最大限度地利用本发明。以下具体实施例应被解释为仅仅是说明性的，而不以任何方式限制本公开内容的其余部分。
除非另有规定，否则本文使用的所有技术和科学术语都具有本发明所属技术领域普通技术人员公知的相同含义。此外，将本文提及的所有出版物、专利申请、专利和其他参考文献以引用方式并入本文中。除非另外指明，否则百分比是指重量百分比(即，％(W/W))。除非另外阐明，否则所有范围均包括端值，如“4至9”包括端值4和9。
本文所描述的产物可任选为成品包装形式。在一个实施例中，所述包装为装有所述组合物的诸如塑料、金属或玻璃管或广口瓶之类的容器。该产品可另外具有用于储存该容器的诸如塑料或纸板盒之类的包装。在一个实施例中，该产品包括本发明的组合物并且具有引导使用者将该组合物施用至皮肤或毛发以处理皮肤老化迹象的说明书。这种说明书可印刷在容器上、标签插页或任何其它包装上。
如本文所用，“局部施用”意指例如用手或涂敷器(例如擦拭物、滚筒或喷雾器)直接涂在或铺展在外部皮肤、头皮或毛发上。
如本文所用，“美容上可接受的”意指该术语描述的成分适于与组织(如，皮肤或毛发)接触使用而不会引起不适当的毒性、不相容性、不稳定性、剌激性、变应性反应等。
在某些实施例中，本发明的组合物适用于处理皮肤老化迹象。本文所用，“皮肤老化迹象”包括存在细纹和皱纹、损失弹性、肤色不均、斑疤。在一个特别优选的实施例中，老化迹象是存在细纹和皱纹和/或损失弹性。
如本文所用，“处理皮肤老化迹象”指减轻、减少、预防、改善或消除上述皮肤老化的存在或迹象。
本文所用，“皱纹”包括微细纹、微皱纹或粗皱纹。皱纹的实例包括但不限于眼睛周围的细纹(例如“鱼尾纹”)、前额和颊皱纹、眉心纹和嘴巴周围的笑纹。
如本文所用，“损失弹性”包括皮肤或组织的弹性或结构完整性的损失，包括但不限于松垂、松弛和松散的组织。弹性或组织结构完整性的损失可由多种因素所致，包括但不限于疾病、衰老、激素变化、机械创伤、环境损害，或者是向组织施用诸如美容品或药物之类的产品的结果。
如本文所用，“肤色不均”意指与弥漫状或斑驳状色素沉着有关的皮肤状况，所述色素沉着可分类为色素沉着过度，例如发炎后色素沉着过度。
如本文所用，“斑疤”意指与发红或红斑相关的皮肤状况。
如本文所用，“化妆品”指保持、恢复、赋予、刺激或增强体美外观或者似乎增进美貌或年轻的美容物质或制品，特别是涉及组织或皮肤的外观时。
如本文所用，“美容上有效量”意指足以处理一种或多种皮肤老化迹象、但低至足以避免严重副作用的生理活性化合物或组合物的量。化合物或组合物的美容上有效量将会随以下因素而变：所治疗的具体病症、最终使用者的年龄和身体状况、所治疗/预防的病症的严重程度、治疗的持续时间、其他治疗的性质、所采用的具体化合物或产品/组合物、所具体采用的美容上可接受的载体等等。
所述组合物包含NFκB抑制剂和抗炎化合物，所述抗炎化合物并非为NFκB抑制剂而且具有低IC50。这两种成分均为皮肤和其他组织提供抗炎有益效果，并且这些抗炎有益效果为互补的。本发明人已吃惊地发现，与NFκB抑制剂混合的具有约70μg/ml或更低的IC50的抗炎化合物抑制IL-1和IL-8细胞因子的增加(所述增加可在其他情况下因使用单独化合物而产生)。
在本发明的一个实施例中，当通过示于实例V中的IL-1α检测分析法测量时，NFκB抑制剂与具有约70μg/ml或更低的IC50的抗炎化合物的组合使得所产生的细胞因子IL-1α降低至少约35％。
在本发明的另一个实施例中，当通过示于实例VIII的IL-8检测分析法测量时，NFκB抑制剂与具有约70μg/ml或更低的IC50的抗炎化合物的组合使得所产生的细胞因子IL-8降低至少约80％。
因此，本发明还提供通过将NFκB抑制剂和下述抗炎化合物的组合局部施用至皮肤或其他组织来使该皮肤或其他组织中所产生的细胞因子IL-1α降低至少约35％(如通过IL-1α检测分析法测得)的方法，所述抗炎化合物并非为NFκB抑制剂并且具有约70μg/ml或更低的IC50。如在下文进一步所述，可以局部用组合物的形式来施用NFκB抑制剂和抗炎化合物的组合。
另外提供了通过将NFκB抑制剂和下述抗炎化合物的组合局部施用至皮肤或其他组织来使该皮肤或其他组织中所产生的细胞因子IL-8降低至少约80％(如通过IL-8检测分析法测得)的方法，所述抗炎化合物并非为NFκB抑制剂并且具有约70μg/ml或更低的IC50。如在下文进一步所述，可以局部用组合物的形式来施用NFκB抑制剂和抗炎化合物的组合。
NFκB 抑制剂
如本文所用，“NFκB抑制剂”意指可抑制细胞转录因子核转录因子k-B(NFκB)的化合物。在一个实施例中，NFκB抑制剂在根据如下文定义的“NFκB抑制测试”进行测试时，在以优选每毫升1微克至每毫升约100微克的浓度测试时具有至少约30％、优选至少约50％、更优选至少约70％、最优选至少约90％的NFκB抑制百分比。也就是说，化合物以在每毫升1微克至每毫升100微克范围内的至少一种浓度下显示出所列出的NFκB抑制百分比。该化合物不必在每毫升1微克至每毫升100微克的所有浓度下提供所列出的NFκB抑制百分比，而是在该范围内的至少一个浓度下提供所列出的NFκB抑制百分比。
在一个优选的实施例中，当以每毫升10微克的浓度测试时，NFκB抑制剂具有至少约35％、优选至少约55％、更优选至少约70％、最优选至少约90％的NFκB抑制百分比。
“NFκB抑制测试”以如下方式进行。使用FB293细胞，其为含有NF-κB的报告基因的稳定转染的人上皮细胞系。它们可从(如)Panomics(Fremont，CA)获得。将FB293以5×104个细胞/mL的密度接种于合适的培养基中，例如补充有10％胎牛血清(Invitrogen，San Diego，CA)的达尔伯克氏改良伊格尔培养基(DMEM)中。在存在测试样品的情况下，用100ng/mL的肿瘤坏死因子α(TNFα，可得自Sigma-Aldrich(St Louis，MO))刺激该FB293细胞。单独地，测试其中未施用测试样品的对照样品。在37℃下使用5％的CO2孵育24小时之后，利用40μl的报告裂解缓冲液(Promega，Madison，WI)来裂解细胞。将20μL的裂解产物等分试样用虫荧光素酶测定试剂盒(Promega)进行测定，并在Lmax发光计(Molecular Devices，Sunnyvale，CA)中计数10秒，数据以相对光单位/秒表示。测试样品的NFκB抑制百分比计算如下：
NFκB抑制＝[1-(L样品/L对照)]*100
其中L样品为样品的发光，L对照为对照的发光。
一种或多种NFκB抑制剂可以任何合适的量存在于本发明组合物中，例如约0.01重量％至约10重量％、优选约0.1％至约20％、更优选约0.1％至约5％、甚至更优选约0.2％至约2％。
在一个实施例中，NFκB抑制剂选自如下化合物：取代的间苯二酚、(E)-3-(4-甲基苯基磺酰基)-2-丙烯腈(如“Bay 11-7082”，可从Sigma-Aldrich(St.Louis，Missouri)商购获得)、四氢姜黄素(如四氢姜黄素CG，可得自Sabinsa Corporation(Piscataway，NJ))、毛泡桐木的提取物以及它们的组合。
在一个优选的实施例中，NFκB抑制剂是取代的间苯二酚。间苯二酚是具有如下结构的二羟基酚化合物(即1，3二羟基苯)：
如本文所用，“取代的间苯二酚”意指在2、4、5或6位中具有至少一个取代基间苯二酚。因而，取代的间苯二酚可具有少至一个且多至四个的取代基。取代的间苯二酚的位置1和3具有-OH羟基，如上所示。
高度优选的是，取代的间苯二酚的所有取代基无苯基(-C6H5芳族)部分。在某些实施例中，所有取代基无(具有或不具有杂原子的)芳族部分。
在另一个实施例中，优选的是取代的间苯二酚的所有取代基无酮官能团(与另外两个碳原子键合的羰基)。
在某些优选的实施例中，取代的间苯二酚的所有取代基既无苯基官能团也无酮官能团。
在某些优选的实施例中，取代的间苯二酚包含至少一个具有5至11个碳原子、优选5至10个碳原子、更优选5至9个碳原子、最优选5至8个碳原子的取代基。在某些其他实施例中，至少一个取代基包含烷基，例如具有上述碳原子数目的烷基。该烷基优选是不饱和的。
在某些实施例中，间苯二酚的4位被取代，在某些实施例中，仅4位被取代。在另一个实施例中，4位置被烷基基团取代。在某些优选的实施例中，取代的间苯二酚包含单个4位取代基，该取代基包含烷基。在某些其他的优选实施例中，取代的间苯二酚包含单个4位取代基，该取代基由与苯环直接键合的烷基组成。
特别合适的取代的间苯二酚包括4-己基间苯二酚和4-辛基间苯二酚，特别是4-己基间苯二酚。4-己基间苯二酚和4-辛基间苯二酚的结构在下面示出：
4-己基间苯二酚可以“SYNOVEA HR”从Sytheon(Lincoln Park，NJ)商购获得。4-辛基间苯二酚可从City Chemical LLC(West Haven，Connecticut)商购获得。
在某些实施例中，取代的间苯二酚在2、4、5或6位具有至少两个取代基。这种取代基可任选连接而形成环，例如任选包含杂原子例如硫或氧的环状脂族烃。例如连接的取代基可包含5至10碳原子，如8至10碳原子，并任选包括1至3杂原子。具有连接2位和3位的环状脂族取代基的合适取代的间苯二酚的例子包括玉米赤霉酮和β-玉米赤霉醇：
玉米赤霉酮和β-玉米赤霉醇可从Sigma Chemicals(St.Louis，Missouri)商购获得。
在某些其他实施例中，取代的间苯二酚具有含卤和/或含亚硝基的取代基。合适的例子含有与苯环直接键合的-Cl或-N＝O。这些取代基可存在于(例如)2和4位、2和6位或4和6位上。二卤取代的间苯二酚的例子为2，6-二氯间苯二酚。二亚硝基取代的间苯二酚的例子为A2，4-二亚硝基间苯二酚：
2，6-二氯间苯二酚和2，4-二亚硝基间苯二酚可得自City Chemical LLC(WestHaven，Connecticut)。
取代的间苯二酚可通过本领域已知的方法制备，例如使用美国专利No.4,337,370中描述的技术制备，将该专利的内容以引用的方式并入本文。
取代的间苯二酚可具有任何合适的分子量。在某些实施例中，取代的间苯二酚的分子量在约175至约300之间的范围内。
泡桐为亚洲原产的一个植物属，其已逐渐传播至欧洲和美国。在日本，泡桐称为日本泡桐，其专指一个物种：毛泡桐(也称为“公主树”)。通常使用的其他名字为“皇后树”、“毛地黄树”、“皇家树”、“泡桐”(中国)和“Odong-Namoo”(韩国)。学名为“毛泡桐”，其具有报告于各种文献中的多个同义词，即“锈毛泡桐”、“兴山桐”和“毛泡桐”。毛泡桐属于“泡桐”科(有时称为“玄参科”)。美国农业部(plants.USDA.gov)植物数据库通过独特符号“PATO2”来鉴别公主树以及为同义名的毛泡桐和锈毛泡桐。
可使用任何合适的毛泡桐木的提取物。一般而言，毛泡桐树的木材包括来自树杆、树枝或这二者的组合的木材。毛泡桐木的合适提取物可源于木屑、木粉和/或小切屑等等。
取代的间苯二酚在组合物中以安全有效量存在，以组合物的重量计，以例如约0.01％至约10％、优选约0.1％至约5％、更优选约0.2％至约2％、甚至更优选约0.5％至约1.5％的量存在。
抗炎化合物
本发明的组合物还包含并非为NFκB抑制剂的抗炎化合物。具体地讲，如通过NFκB抑制测试测得，当以至多约每毫升100微克的浓度测试时，抗炎化合物具有低于约30％、优选低于约20％、更优选低于约10％的NFκB抑制百分比。即，化合物在至多约每毫升100微克的所有浓度下均显示出低于约30％、优选低于约20％、更优选低于约10％的NFκB抑制百分比。
在一个优选的实施例中，当以至多约每毫升10微克的浓度测试时，抗炎化合物具有低于约30％、优选低于约20％、更优选低于约10％的NFκB抑制百分比。
对于本文所示的抗炎分析检测法中的白细胞介素2，抗炎化合物具有约70μg/ml或更低的IC50(化合物实现50％的发炎抑制的浓度)。在一个优选的实施例中，抗炎化合物的IC50为约50μg/ml或更低、优选约40μg/ml或更低、更优选约30μg/ml或更低。
抗炎检测分析法评估试剂降低通过利用T-细胞受体(TCR)激活剂植物血细胞凝集素(PHA)刺激的人淋巴细胞产生的细胞因子的能力，并且按下述方式来进行。通过白细胞单采术从健康成年男性采集人白细胞，然后在无血清淋巴细胞生长培养基(ExVivo-15，Biowhittaker，Walkersville，Md.)中调整为1×106细胞/mL的密度。按照所公开的方法(Hamamoto Y.等人，Exp Dermatol 2：231-235，1993)，在存在或不存在测试样品的情况下利用10μg/mL的PHA来刺激PBL。在37℃下使用5％的CO2孵育48小时之后，去除上清液，并且使用市售的多重细胞因子检测套件来评估细胞因子含量。
具有约70μg/ml或更低的IC50的合适抗炎化合物包括下述物质：
黄柏外皮提取物(PCE)
甘菊(小白菊)
姜(生姜)
银杏(银杏属)
黄栌(黄栌属)
枸杞子(枸杞)
奶蓟提取物(水飞蓟属)
忍冬(忍冬属)
秘鲁香胶(秘鲁香树)
鼠尾草(药用鼠尾草)
越橘提取物(越橘)
苋菜油(繁穗苋)
石榴(石榴科)
巴拉圭茶(巴拉圭茶叶提取物)
百合花提取物(百合)
橄榄叶提取物(橄榄)
根皮素(苹果提取物)
啤酒花(蛇麻草：啤酒花)提取物
甘草查耳酮(甘草：胀果甘草提取物成分)
馨敏舒(红没药醇和姜提取物)
在某些优选实施例中，抗炎化合物选自：黄柏外皮提取物(PCE)、甘菊(小白菊)、银杏(银杏属)、黄栌(黄栌属)、枸杞子(枸杞)、奶蓟提取物(水飞蓟属)、苋菜油(繁穗苋)、石榴(石榴科)、巴拉圭茶(巴拉圭茶叶提取物)、百合花提取物(百合)、橄榄叶提取物(橄榄)和根皮素(苹果提取物)。
在某些更优选的实施例中，抗炎化合物选自：甘菊(小白菊)、枸杞子(枸杞)、奶蓟提取物(水飞蓟属)、苋菜油(繁穗苋)、石榴(石榴科)、巴拉圭茶(巴拉圭茶叶提取物)、百合花提取物(百合)、橄榄叶提取物(橄榄)和根皮素(苹果提取物)。
“甘菊的提取物”意指(例如)可根据名称为“PARTHENOLIDEFREE BIOACTIVE INGREDIENTS FROM FEVERFEW(TANACETUMPARTHENIUM)AND PROCES SES FOR THEIR PRODUCTION”(得自甘菊(小白菊)的不含小白菊内酯的生物活性成分及其制备方法)的美国专利申请公开No.2007/0196523中设置的细节制备的植株“小白菊”的提取物。一种尤其合适的甘菊提取物可以约20％的活性甘菊从IntegratedBotanical Technologies(Ossining，NY)商购获得。
本发明的组合物可包含美容上有效量的一种或多种抗炎化合物。该组合物优选包含基于活性物质计的约0.1％至约10％、更优选约0.5％至约5％的第二抗炎化合物。
在本发明组合物中，NFκB抑制剂与抗炎化合物的重量比可为变化的。例如，NFκB抑制剂和抗炎化合物可以约0.001至约100、优选约0.01至约10、更优选约0.1至约10的重量浓度比(重量浓度比通过用NFκB抑制剂的重量浓度除以抗炎化合物的重量浓度来确定)存在。
局部用组合物
本发明的组合物可局部施用至人皮肤或毛发。除了第一和第二抗炎化合物，该组合物还可包含美容上可接受的局部用载体，该局部用载体可为组合物的约50重量％至约99.99重量％(如，组合物的约80重量％至约99重量％)。在本发明的一个优选的实施例中，美容上可接受的局部用载体包括水。
可将组合物制备成多种产品类型，包括但不限于洗剂、霜剂、凝胶剂、棒剂、喷雾剂、油膏剂、清洁液体洗剂和固体皂剂、洗发剂和毛发调理剂、毛发固定剂、糊剂、泡沫剂、粉末剂、摩丝、剃须膏、擦拭物、贴剂、水凝胶、成膜产品、面膜和皮肤膜剂、膜剂和化妆品如粉底以及睫毛膏。这些产品类型可含有几种类型的美容上可接受的局部用载体，包括(但不限于)溶液、悬浮液、乳状液(如微乳液和纳米乳液)、凝胶、固体和脂质体。下面是这类载体的非限制性例子。其他的载体可由本领域普通技术人员配制。
可用于本发明的组合物能配制成溶液。溶液通常包含水性溶剂或有机溶剂(例如，约50％至约99.99％或约90％至约99％的美容上可接受的水性溶剂或有机溶剂)。合适的有机溶剂的例子包括：丙二醇、聚乙二醇(200-600)、聚丙二醇(425-2025)、甘油、1，2，4-丁三醇、山梨醇酯、1，2，6-己三醇、乙醇以及它们的混合物。
可用于本主题发明的组合物可配制成包含润肤剂的溶液。此类组合物优选包含约2％至约50％的一种或多种润肤剂。如本文所用，“润肤剂”是指用于例如通过预防水分经表皮从皮肤流失来预防或缓解干燥的材料。润肤剂的例子包括但不限于植物油、矿物油、脂族酯等。
洗剂可由此类溶液制成。洗剂通常包含约1％至约20％(例如，约5％至约10％)的一种或多种润肤剂和约50％至约90％(例如，约60％至约80％)的水分。
可由溶液配制的另一种产品是霜剂。霜剂通常包含约5％至约50％(例如，约10％至约20％)的一种或多种润肤剂和约45％至约85％(例如，约50％至约75％)的水分。
尽管优选的是本发明的组合物包括水，但是作为另一种选择，组合物可以是无水的或者是不含水但含有机和/或硅树脂溶剂、油、类脂和蜡的膏剂。膏剂可包含简单的动物或植物油基质或半固体碳氢化合物。油膏剂可含有约2％至约10％的一种或多种润肤剂和约0.1％至约2％的一种或多种增稠剂。
组合物可以配制为乳状液。如果局部用载体是乳状液，则约1％至约10％(如，约2％至约5％)的局部用载体包含乳化剂。乳化剂可以为非离子型、阴离子型或阳离子型。合适的乳化剂的例子包括个人护理和化妆品配方领域中通常鉴定为合适乳化剂的那些。
洗剂和霜膏可配制成乳状液。通常此类乳液包含0.5％至约5％的乳化剂。这种霜剂通常含有约1％至约20％(如约5％至约10％)的一种或多种润肤剂；约20％至约80％(如30％至约70％)的水；以及约1％至约10％(如约2％至约5％)的一种或多种乳化剂。
水包油和油包水型单乳液护肤制剂，例如洗剂和软膏是化妆品领域所熟知的，并且可用于本主题发明。多相乳状液组合物(例如水包油包水型或油包水包油型)也可用于本主题发明。通常，此类单相乳状液或多相乳状液含有水分、润肤剂和乳化剂作为其基本成分。
本发明的组合物还可配制成凝胶(例如，使用合适的胶凝剂制成的水性凝胶、醇类凝胶、醇/水型凝胶或油性凝胶)。用于水性凝胶和/或醇类凝胶的适当胶凝剂包括(但不限于)天然树胶、丙烯酸和丙烯酸酯聚合物和共聚物以及纤维素衍生物(例如羟甲基纤维素和羟丙基纤维素)。用于油(例如矿物油)的适当胶凝剂包括(但不限于)氢化丁烯/乙烯/苯乙烯共聚物和氢化乙烯/丙烯/苯乙烯共聚物。此类凝胶通常包含介于约0.1重量％和5重量％之间的此类胶凝剂。
本发明的组合物也可配制成固体制剂(例如蜡基棒、条皂组合物、粉末或含有粉末的擦拭物)。
除了前述的组分外，用于本主题发明的组合物还可包含各种各样的其他油溶性物质和/或水溶性物质，这些物质通常用于组合物中，按本领域既定的水平施用于皮肤和头发。
其他美容活性剂
在一个实施例中，组合物还包含另一种美容活性剂。如本文所用，“美容活性剂”是对皮肤或毛发具有美容或治疗效果的化合物(如合成化合物或从天然来源或天然提取物分离的化合物)，包括、但不限于抗痤疮剂、控油剂、抗微生物剂、其他抗炎剂、抗霉菌剂、抗寄生虫剂、外用止痛剂、防晒剂、光防护剂、抗氧化剂、角质层分离剂、表面活性剂、保湿剂、营养剂、维生素、能量增强剂、防汗剂、收敛剂、除臭剂、固化剂、抗硬角质剂和用于毛发和/或皮肤调理的试剂。
在一个实施例中，所述试剂选自(但不限于)羟基酸、过氧化苯甲酰、D-泛醇、甲氧基肉桂酸辛酯、二氧化钛、水杨酸辛酯、胡莫柳酯、阿伏苯宗、类胡萝卜素、胺(如neutrol)、诸如视黄醇和视黄基棕榈酸酯之类的类视色素、神经酰胺、多不饱和脂肪酸、必需脂肪酸、酶、酶抑制剂、矿物质、诸如雌激素之类的激素、诸如氢化可的松之类的类固醇、2-二甲基氨乙醇、诸如氯化铜之类的铜盐、诸如Cu:Gly-His-Lys之类的含铜肽、辅酶Q10、肽、诸如脯氨酸之类的氨基酸、维生素、乳糖酸、乙酰基-辅酶A、烟酸、核黄素、硫胺素、核糖、诸如NADH和FADH2之类的电子转运蛋白和诸如芦荟、甘菊、麦片之类的其他植物提取物以及它们的衍生物和混合物。美容活性剂通常将以组合物的约0.001重量％至约20重量％(如，约0.005％至约10％，例如约0.01％至约5％)的量存在于本发明的组合物中。
维生素的例子包括但不限于维生素A、维生素B(例如维生素B3、维生素B5和维生素B12)、维生素C、维生素K和维生素E的不同形式(如α、β、γ或Δ生育酚)或它们的混合物以及它们的衍生物。
羟基酸的例子包括，但不限于乙醇酸、乳酸、苹果酸、水杨酸、柠檬酸和酒石酸。
抗氧化剂的例子包括(但不限于)水溶性抗氧化剂，例如巯基化合物和它们的衍生物(如，焦亚硫酸钠和N-乙酰基-半胱氨酸)、硫辛酸和二氢硫辛酸、白藜芦醇、乳铁蛋白以及抗坏血酸和抗坏血酸衍生物(如，抗坏血酸棕榈酸酯和抗坏血酸多肽)。适用于本发明的组合物中的油溶性抗氧化剂包括但不限于丁基化羟基甲苯、类视色素(如，视黄醇和视黄基棕榈酸酯)、生育酚类(如，生育酚乙酯)、生育三烯酚类和泛醌。包含适用于本发明的组合物中的抗氧化剂的天然提取物包括但不限于：包含黄酮类和异黄酮类以及它们的衍生物(如，染料木黄酮和二联玉米蛋白)的提取物、包含白藜芦醇的提取物等。此类天然提取物的例子包括葡萄籽、绿茶、松树皮和蜂胶。
其他材料
各种其他材料也可以存在于组合物中，如本领域所公知的。这些物质包括湿润剂、pH调节剂、螯合剂(如EDTA)、芳香剂和防腐剂(如对羟苯甲酸酯)。
水或醇溶性染料可能也适合用于本发明的组合物。适用于本发明组合物的染料的例子包括焦糖、胭脂红、荧光素衍生物、甲氧补骨脂素、三甲补骨脂内酯、偶氮染料、蒽醌染料、蓝薁、愈创薁、1，4-二甲基薁(chamuzulene)、赤藓红、孟加拉玫瑰红、根皮红、cyanosin、daphinin、曙红G、cosin 10B、酸性红51、红染料4、红染料40、蓝染料1和黄染料5或它们的混合物。
当使用时，基于组合物的总重量，组合物中染料的量可在约0.0001至约0.1、优选约0.0025至约0.025重量百分比之间变化。
包含本发明此类组合物的组合物、制剂和产品可以利用本领域普通技术人员所知的方法来制备。
使用方法
可将本发明的组合物局部施用至需要处理如上所述的一种或多种皮肤老化迹象的哺乳动物皮肤。在一个实施例中，可将组合物施用至需要处理细纹和皱纹和/或弹性损失的皮肤。可根据合适的处理方案，如每月、每周、每隔一天、每天、每天两次等，将组合物施用至需要这种处理的皮肤。
在某些实施例中，本发明的组合物还可用于处理与皮肤相关的其他需要。例如，本发明的组合物可用于处理发炎后色素沉着过度、用于减小毛孔大小、痤疮处理、用于减少皮脂产生以及用于减轻疤痕。在某些其他实施例中，可将本发明的组合物与机械或物理表皮剥脱处理(例如微晶磨皮处理)同时施用或在该处理的数小时内施用，或与化学剥脱剂或角质层分离剂例如水杨酸同时施用。在某些其他实施例中，可将本发明的组合物施用至粘膜或其它组织例如阴道组织、口腔组织或眼组织。在某些其他实施例中，可将本发明的组合物施用至轻度伤口或术后部位以促进愈合、施用至昆虫叮咬处、施用至毒藤皮肤病症或相似皮肤状况，或通常用于减轻发痒。在某些其他实施例中，施用本发明的组合物以减轻皮肤刺激。所述刺激可具有因护肤和美容产品中的成分(例如类视色素及其衍生物、过氧苯甲酰、α-羟基酸及其衍生物、水杨酸、表面活性剂、天然植物提取物、防晒活性物质、脲以及防腐剂等)导致的外部起源。所述刺激可具有其他外部起源，例如太阳、风或剃须。所述刺激也可由内部疾病状况导致，所述内部疾病状况例如痤疮、红斑痤疮、特应性皮炎以及其他疾病状态。
据信，本领域的技术人员可根据本文的描述最大限度地利用本发明。以下具体实施例应被解释为仅仅是说明性的，而不以任何方式限制本公开内容的其余部分。以下非限制性实例进一步说明了本发明。
实例I
对如下测试样品进行了上述“NFκB抑制测试”：Bay 11-7082测试样品(Sigma-Aldrich，St.Louis，MO)、四氢姜黄素CG(Sabinsa Corporation，Piscataway，NJ)以及多种浓度的4-己基间苯二酚。结果在表1中示出，其中对测试样品和对照样品记录NF-κB报告基因激活(发光，L)。另外记录NF-κB抑制百分比。
表1
Bay 11-7082和四氢姜黄素CG显示出强的NF-κB抑制。出乎意料的是，4-己基间苯二酚也导致NFκB激活显著减少。更出乎意料的是，4-己基间苯二酚即使在低浓度时也显示出显著的NF-κB抑制。
实例II
对各自浓度为10μg/ml的一系列取代的间苯二酚进行了上述“NFκB抑制测试”。结果在表2中示出。
表2
从表2中的数据可以看出，仅含无苯基官能团的取代基的取代间苯二酚、仅含无酮官能团的取代基的取代间苯二酚以及包含具有5至11个碳原子的取代基的取代间苯二酚提供较好的NFκB抑制。
实例III
对多种试剂进行上述NFκB抑制测试和抗炎检测分析法。结果在下文的表3a和3b中示出。
表3a列出了根据本发明的具有约70μg/ml或更低的IC50值的抗炎化合物。表3b列出了具有高于70μg/ml的IC50值的对比抗炎化合物。
表3a
表3b
实例IV
使用下文表4中所示的成分来制备根据本发明的组合物：发明实例Ex.1。
表4
| INCI名 | 商品名 | 重量％ |
| 去离子水 | 纯化水 | 77％ |
| 戊二醇 | HYDROLITE 5 | 5％ |
| 己基间苯二酚 | SYNOVEA HR | 1％ |
| 油质体 | NATRULON OSF油质体 | 10％ |
| 苯甲酸C12-15烷基酯 | Finsolv TN | 4％ |
| 丙烯酰二甲基牛磺酸铵/VP共聚物 | ARISTOFLEX AVC | 2％ |
| 小白菊(甘菊)叶/花/茎汁液 | 小白菊提取物 | 1％ |
FINSOLV TN可得自Finetex，Inc.(Elmwood Park，NJ)
HYDROLITE 5可得自Symrise(Teterboro，NJ)
SYNOVEA HR可得自Sytheon(Lincoln Park，NJ)
ARISTOFLEX AVC可得自Clariant(Frankfurt，德国)
NATRULON OSF油质体得自Lonza(Allendale，NJ)
通过如下方法制备该组合物。将Synovea HR称重并溶解于HYDROLITE 5中，加入去离子水以形成A相。将油质体与Finsolv TN混合以形成B相。在持续混合下将B相非常缓慢地加入至A相。继续混合15分钟直至形成均一的乳剂。在持续混合下将ARISTOFLEX快速加入至上述乳剂中以获得稠的、平滑且均匀的制剂。
实例V
对多种试剂执行IL-1α检测分析法，以研究促炎介质IL-1α细胞因子在人上皮细胞中的释放。
按下文所述来执行IL-1α检测分析法。KB细胞得自ATCC(ATCC#CCL-17，Manassas，VA)并且以5000个细胞/孔的密度铺板在96孔的组织培养处理板中的添加10％胎牛血清(Invitrogen Corp.，San Diego，CA)的达尔伯克改良伊格尔培养基(DMEM)内。在48小时之后，利用下文所述的指定浓度的试剂来处理细胞24小时，然后收集上清液并且利用市售套件(Millipore Corp.，Billerica，MA)来分析IL-1α细胞因子的释放。结果在下表5中示出。
表5
结果表明，诸如4-己雷琐辛和四氢姜黄素之类的NF-κB抑制剂尽管能够抑制NF-κB，但可增加细胞因子IL-1α的释放。
实例VI
执行如实例5中所述的其他IL-1α检测分析法。为了易于比较，将4-己雷琐辛、根皮素以及它们的组合的IL-1α的报告增加值相对4-己雷琐辛(20μg/mL，比较例2)进行归一化。将四氢姜黄素、甘菊以及它们的组合的IL-1α的报告增加值相对四氢姜黄素(20μg/mL，比较例3)进行归一化。结果在下表6中示出。
表6
结果表明，尽管NF-κB抑制剂可促使产生细胞因子IL-1α，但可通过将NF-κB抑制剂与具有约70μg/ml或更低的IC50的抗炎化合物(如，甘菊或根皮素)混合来逆转这种效果。
实例VII
执行如实例5中所述的其他IL-1α检测分析法。为了易于比较，将IL-1α的报告增加值相对4-己雷琐辛(20μg/mL，比较例2)进行归一化。
表7
这些结果表明，NF-κB抑制剂和具有高于约70μg/ml的IC50的抗炎化合物的组合不可与NF-κB抑制剂和具有约70μg/ml或更低的IC50的抗炎化合物的组合一样显著地降低细胞因子IL-1α的产生。上述数据表明，NF-κB抑制剂与具有高于约70μg/ml的IC50的抗炎化合物的组合使得所产生的细胞因子IL-1α减少低于35％。
应该指出的是，在比较例9-14中，大豆未溶于测试培养基中而是分散的。
实例VIII
使用实例5中所述的方法对一系列组合物执行IL-8检测分析法，不同的是分析的细胞因子为IL-8。对各个样品计算IL-8的减少百分比。结果在表8中示出。对于含有NF-κB抑制剂和抗炎化合物的组合的样品，报告出IL-8的减少百分比(相对于对应剂量的抗炎化合物的IL-8的减少百分比)。
表8
结果表明，与任一单独化合物的性能相比，NF-κB抑制剂与具有约70μg/ml或更低的IC50的抗炎化合物的组合极大地降低了IL-8的表达。
实例IX
执行如实例8所述的另一个IL-8检测分析法，不同的是改变了NF-κB抑制剂与具有约70μg/ml或更低的IC50的抗炎化合物的比率。结果在下表9中示出。
表9
这些结果表明，在多个重量比的整个范围上(对于发明实例Ex.13、14和15分别为10∶1、1∶1和1∶10的重量比)可观察到NF-κB抑制剂与具有约70μg/ml或更低的IC50的抗炎化合物的组合的性能的显著改善。
总体而言，本发明的抗炎共混物使得炎性细胞因子IL-1和IL-8均减少，同时还通常提供NFκB抑制。
应当了解，虽然已结合本发明的具体实施方式描述了本发明，但是前述描述旨在说明而非限制由随附权利要求书所限定的本发明的范围。其他方面、优点和修改均在权利要求书内。
Claims (10)
1.一种组合物，包含：
NFκB抑制剂；和
抗炎化合物，所述抗炎化合物并非为NFκB抑制剂并且具有约70μg/ml或更低的IC50。
2.根据权利要求1所述的组合物，其中所述抗炎化合物具有约50μg/ml或更低的IC50。
3.根据权利要求1所述的组合物，其中所述抗炎化合物具有约40μg/ml或更低的IC50。
4.根据权利要求1所述的组合物，其中所述抗炎化合物为提取物，所述提取物选自黄柏外皮提取物(PCE)、甘菊(小白菊)、银杏(银杏属)、黄栌(黄栌属)、枸杞子(枸杞)、奶蓟提取物(水飞蓟属)、苋菜油(繁穗苋)、石榴(石榴科)、巴拉圭茶(巴拉圭茶叶提取物)、百合花提取物(百合)、橄榄叶提取物(橄榄)、根皮素(苹果提取物)以及它们的组合。
5.根据权利要求1所述的组合物，其中所述抗炎化合物为提取物，所述提取物选自甘菊(小白菊)、枸杞子(枸杞)、奶蓟提取物(水飞蓟属)、苋菜油(繁穗苋)、石榴(石榴科)、巴拉圭茶(巴拉圭茶叶提取物)、百合花提取物(百合)、橄榄叶提取物(橄榄)、根皮素(苹果提取物)以及它们的组合。
6.根据权利要求1所述的组合物，其中所述NFκB抑制剂选自取代的间苯二酚、(E)-3-(4-甲基苯磺酰基)-2-丙烯腈、四氢姜黄素、毛泡桐木的提取物以及它们的组合。
7.根据权利要求1所述的组合物，其中所述NFκB抑制剂选自取代的间苯二酚、四氢姜黄素以及它们的组合。
8.根据权利要求4所述的组合物，其中所述NFκB抑制剂选自取代的间苯二酚、四氢姜黄素以及它们的组合。
9.根据权利要求5所述的组合物，其中所述NFκB抑制剂选自：取代的间苯二酚、四氢姜黄素以及它们的组合。
10.根据权利要求1所述的组合物，其中所述NFκB抑制剂和所述抗炎化合物以约1∶10至约10∶1的重量比存在。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24799209P | 2009-10-02 | 2009-10-02 | |
| US61/247,992 | 2009-10-02 | ||
| PCT/US2010/051080 WO2011041648A1 (en) | 2009-10-02 | 2010-10-01 | Compositions comprising an anti-inflammatory blend |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102573820A true CN102573820A (zh) | 2012-07-11 |
| CN102573820B CN102573820B (zh) | 2015-11-25 |
Family
ID=43127098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080045045.0A Expired - Fee Related CN102573820B (zh) | 2009-10-02 | 2010-10-01 | 包含抗炎共混物的组合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8318217B2 (zh) |
| EP (1) | EP2482809B1 (zh) |
| KR (1) | KR101750296B1 (zh) |
| CN (1) | CN102573820B (zh) |
| BR (1) | BR112012007512A2 (zh) |
| CA (1) | CA2774026C (zh) |
| ES (1) | ES2674569T3 (zh) |
| HK (1) | HK1171954A1 (zh) |
| IN (1) | IN2012DN02441A (zh) |
| RU (1) | RU2554766C2 (zh) |
| WO (1) | WO2011041648A1 (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028645A (zh) * | 2009-10-02 | 2011-04-27 | 强生消费者公司 | 包含nfkb抑制剂和非类视色素胶原促进剂的组合物 |
| CN102113978A (zh) * | 2009-10-02 | 2011-07-06 | 强生消费者公司 | 包含nfkb抑制剂和弹性蛋白原促进剂的组合物 |
| US9370474B2 (en) | 2009-10-02 | 2016-06-21 | Johnson & Johnson Consumer Inc. | High-clarity aqueous concentrates of 4-hexylresorcinol |
| CN107184482A (zh) * | 2017-06-26 | 2017-09-22 | 上海家化联合股份有限公司 | 马黛茶提取物及其在皮肤外用剂中的应用 |
| US10307352B2 (en) | 2012-09-24 | 2019-06-04 | Johnson & Johnson Consumer Inc. | Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168279B2 (en) | 2010-08-19 | 2015-10-27 | Johnson & Johnson Consumer Inc. | Compositions comprising paulownin and/or Paulownia extracts and uses thereof |
| CN103228261B (zh) * | 2010-08-19 | 2015-12-16 | 强生消费者公司 | 包含泡桐素和/或泡桐属提取物的组合物及其用途 |
| US9173913B2 (en) | 2010-08-19 | 2015-11-03 | Johnson & Johnson Consumer Inc. | Compositions comprising Paulownia tomentosa wood extracts and uses thereof |
| US9168219B2 (en) | 2010-08-19 | 2015-10-27 | Johnson & Johnson Consumer Inc. | Compositions comprising Paulownia tomentosa wood extracts and uses thereof |
| US9387349B2 (en) | 2010-08-19 | 2016-07-12 | Johnson & Johnson Consumer Inc. | Compositions comprising Paulownia tomentosa wood extracts and uses thereof |
| US9168207B2 (en) | 2010-08-19 | 2015-10-27 | Johnson & Johnson Consumer Inc. | Compositions comprising Paulownia tomentosa wood extracts and uses thereof |
| US9161958B2 (en) | 2010-08-19 | 2015-10-20 | Johnson & Johnson Consumer Inc. | Methods of treating cellulite |
| US9962326B2 (en) | 2010-08-19 | 2018-05-08 | Johnson & Johnson Consumer Inc. | Compositions comprising paulownia tomentosa wood extracts and uses thereof |
| US8758731B2 (en) | 2012-06-29 | 2014-06-24 | Johnson & Johnson Consumer Companies, Inc. | Skin lightening by topical application of 1-hydroxyl 3,5-bis(4′hydroxyl styryl)benzene |
| EP2866779A2 (en) * | 2012-06-29 | 2015-05-06 | Johnson & Johnson Consumer Companies, Inc. | Topical application of 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene |
| US8846013B2 (en) | 2012-06-29 | 2014-09-30 | Johnson & Johnson Consumer Companies, Inc. | Topical application of 1-hydroxyl-3,5-BIS(4′hydroxy styryl)benzene |
| US10130576B2 (en) | 2012-11-13 | 2018-11-20 | Johnson & Johnson Consumer Inc. | Oral care compositions |
| EP2919748B1 (en) | 2013-05-01 | 2018-03-21 | The Procter and Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
| US20150272837A1 (en) | 2014-03-27 | 2015-10-01 | Johnson & Johnson Consumer Companies, Inc. | Topical Compositions Comprising A Resorcinol and Powders |
| JP6657192B2 (ja) | 2014-09-12 | 2020-03-04 | ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ | メラニン合成を阻害するための美容組成物 |
| CN106177403A (zh) * | 2016-09-19 | 2016-12-07 | 四川易创生物科技有限公司 | 一种可有效治疗肝肾阴虚的汤剂药物及其制备方法 |
| US20200405603A1 (en) | 2019-06-25 | 2020-12-31 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using infrared light and resorcinols |
| US10537534B1 (en) | 2019-06-25 | 2020-01-21 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using visible light and resorcinols |
| WO2021018936A1 (en) * | 2019-07-29 | 2021-02-04 | Echo Pharmaceuticals B.V. | Treatment of inflammatory skin conditions |
| KR102346078B1 (ko) * | 2020-01-15 | 2022-01-03 | 경희대학교 산학협력단 | 엉겅퀴 발효물 제조방법 및 이의 방법으로 제조된 항염증용 조성물 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101227916A (zh) * | 2005-05-24 | 2008-07-23 | 维尔金有限公司 | 预防和治疗发炎相关状况的组合物和方法 |
| US20080305059A1 (en) * | 2007-06-06 | 2008-12-11 | Chaudhuri Ratan K | Skin lightening compositions and methods |
| WO2008157833A1 (en) * | 2007-06-21 | 2008-12-24 | Puramed Bioscience Inc. | Compositions and methods for treating and preventing migrainous headaches and associated symptoms |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1649670A (en) | 1923-11-08 | 1927-11-15 | Sharp & Dohme Inc | Hexyl resorcinol |
| US3193507A (en) | 1961-08-30 | 1965-07-06 | Henry R Jacobs | Method of cleaning glass |
| US4093667A (en) | 1977-03-14 | 1978-06-06 | Continental Oil Company | Preparation of 4-n-hexylresorcinol |
| US4337370A (en) | 1979-11-08 | 1982-06-29 | Sumitomo Chemical Company, Limited | Process for the preparation of resorcinol derivatives |
| JPH0651619B2 (ja) | 1988-05-09 | 1994-07-06 | 株式会社クラレ | 美白剤 |
| US5705145A (en) | 1996-08-21 | 1998-01-06 | E-L Management Corp. | Skin tanning compositions and method |
| JPH11100324A (ja) * | 1997-09-29 | 1999-04-13 | Lion Corp | ニキビ治療用組成物 |
| JP4004182B2 (ja) | 1999-05-24 | 2007-11-07 | ポーラ化成工業株式会社 | 乳化組成物 |
| JP4615671B2 (ja) | 2000-04-20 | 2011-01-19 | ポーラ化成工業株式会社 | 炎症存在下使用用のしわ形成又は皮膚の弾力喪失の防止剤 |
| DE10118894A1 (de) | 2001-04-18 | 2002-10-24 | Goldwell Gmbh | Verfahren zum oxidativen Färben von menschlichen Haaren |
| DE10118889A1 (de) | 2001-04-18 | 2002-10-24 | Goldwell Gmbh | Haarfärbemittel |
| US6863897B2 (en) | 2002-03-22 | 2005-03-08 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Stabilization of resorcinol derivatives in cosmetic compositions |
| US6869598B2 (en) | 2002-03-22 | 2005-03-22 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Stabilization of sunscreens in cosmetic compositions |
| AU2003220567A1 (en) | 2002-03-28 | 2003-10-13 | Johnson And Johnson Consumer Companies, Inc. | Compostions for darkening the skin |
| US6852310B2 (en) | 2002-08-23 | 2005-02-08 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Skin lightening agents, compositions and methods |
| JP3962666B2 (ja) | 2002-09-13 | 2007-08-22 | 株式会社クラレ | 皮膚外用剤 |
| US20040109832A1 (en) | 2002-12-09 | 2004-06-10 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Di-substituted resorcinols as skin lightening agents |
| US6875425B2 (en) | 2002-12-12 | 2005-04-05 | Unilever Home & Personal Care Usa | Skin lightening agents, compositions and methods |
| GB2398496A (en) | 2003-02-20 | 2004-08-25 | Reckitt Benckiser Healthcare | Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles |
| EP1613295A1 (en) | 2003-04-15 | 2006-01-11 | Unilever N.V. | Use of alkyl resorcinols in the treatment of acne |
| GB2438999B (en) | 2003-06-13 | 2008-01-16 | Engelhard Lyon | Stimulation of the synthesis and of the activity of an isoform of lysyl oxidase-like LOXL for stimulating the formation of elastic fibres |
| US7320797B2 (en) * | 2003-08-29 | 2008-01-22 | Bioderm Research | Antiaging cosmetic delivery systems |
| GB2415135A (en) | 2004-06-15 | 2005-12-21 | Reckitt Benckiser | Improvements in and relating to depilatory compositions |
| US20060019002A1 (en) | 2004-07-26 | 2006-01-26 | Harvest Food Co., Ltd. | Method for processing, storing and transporting garlic |
| US20060120975A1 (en) | 2004-12-02 | 2006-06-08 | Colgate-Palmolive Company | Oral care composition comprising a phenolic compound and antioxidant vitamins and vitamin derivatives |
| US8278359B2 (en) | 2005-02-25 | 2012-10-02 | Johnson & Johnson Consumer Companies, Inc. | Compositions containing amines and use thereof to treat acne or reduce the appearance of oil or pores on the skin |
| US20060210497A1 (en) | 2005-03-18 | 2006-09-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Novel resorcinol derivatives |
| US20060210498A1 (en) | 2005-03-18 | 2006-09-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Novel resorcinol derivatives for skin |
| US20060264497A1 (en) | 2005-03-28 | 2006-11-23 | Zeligs Michael A | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health |
| JP2006327965A (ja) | 2005-05-25 | 2006-12-07 | Pola Chem Ind Inc | 皮膚外用剤とその適用 |
| WO2007094200A1 (ja) | 2006-02-14 | 2007-08-23 | Pola Chemical Industries Inc. | 美白用の化粧料 |
| CA2643255A1 (en) | 2006-02-21 | 2007-08-30 | Integrated Botanical Technologies, Llc | Parthenolide free bioactive ingredients from feverfew (tanacetum parthenium) and processes for their production |
| JP2007254412A (ja) | 2006-03-24 | 2007-10-04 | Kuraray Co Ltd | シワの予防及び／又は改善のための皮膚外用剤 |
| US20080026974A1 (en) | 2006-07-27 | 2008-01-31 | Barnhart Ronald A | Antimicrobial hand wash |
| US20100124539A1 (en) | 2006-10-16 | 2010-05-20 | Hanson Medical, Inc. | Cosmetic preparations |
| JP5015620B2 (ja) | 2007-01-30 | 2012-08-29 | 株式会社クラレ | 皮膚外用剤 |
| US20080241085A1 (en) | 2007-03-29 | 2008-10-02 | Lin Connie B | Compositions for use in darkening the skin |
| US20080286217A1 (en) | 2007-05-14 | 2008-11-20 | Chaudhuri Ratan K | Sunscreen compositions and methods |
| WO2008140673A1 (en) | 2007-05-14 | 2008-11-20 | Sytheon Ltd. | Skin treatment compositions and methods |
| JP2009084164A (ja) | 2007-09-27 | 2009-04-23 | Septem Soken:Kk | 老化防止剤 |
| US20090087395A1 (en) | 2007-10-01 | 2009-04-02 | Lin Connie B | Compositions for use in darkening the skin |
| JP2011512409A (ja) * | 2008-02-20 | 2011-04-21 | イーエルシー マネージメント エルエルシー | 皮膚を美白するための局所組成物及び方法 |
| US9676696B2 (en) | 2009-01-29 | 2017-06-13 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
| US20110081430A1 (en) | 2009-10-02 | 2011-04-07 | Simarna Kaur | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER |
| US8906432B2 (en) | 2009-10-02 | 2014-12-09 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter |
| US20110081305A1 (en) | 2009-10-02 | 2011-04-07 | Steven Cochran | Compositions comprising a skin-lightening resorcinol and a skin darkening agent |
| US8084504B2 (en) | 2009-10-02 | 2011-12-27 | Johnson & Johnson Consumer Companies, Inc. | High-clarity aqueous concentrates of 4-hexylresorcinol |
-
2010
- 2010-10-01 CN CN201080045045.0A patent/CN102573820B/zh not_active Expired - Fee Related
- 2010-10-01 IN IN2441DEN2012 patent/IN2012DN02441A/en unknown
- 2010-10-01 KR KR1020127011431A patent/KR101750296B1/ko active IP Right Grant
- 2010-10-01 EP EP10762844.8A patent/EP2482809B1/en active Active
- 2010-10-01 CA CA2774026A patent/CA2774026C/en not_active Expired - Fee Related
- 2010-10-01 RU RU2012117746/15A patent/RU2554766C2/ru not_active IP Right Cessation
- 2010-10-01 BR BR112012007512A patent/BR112012007512A2/pt not_active IP Right Cessation
- 2010-10-01 WO PCT/US2010/051080 patent/WO2011041648A1/en active Application Filing
- 2010-10-01 US US12/896,250 patent/US8318217B2/en not_active Expired - Fee Related
- 2010-10-01 ES ES10762844.8T patent/ES2674569T3/es active Active
-
2012
- 2012-12-12 HK HK12112862.6A patent/HK1171954A1/zh not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101227916A (zh) * | 2005-05-24 | 2008-07-23 | 维尔金有限公司 | 预防和治疗发炎相关状况的组合物和方法 |
| US20080305059A1 (en) * | 2007-06-06 | 2008-12-11 | Chaudhuri Ratan K | Skin lightening compositions and methods |
| WO2008157833A1 (en) * | 2007-06-21 | 2008-12-24 | Puramed Bioscience Inc. | Compositions and methods for treating and preventing migrainous headaches and associated symptoms |
Non-Patent Citations (1)
| Title |
|---|
| YU-LI LIN ET AL: "Theaflavin-3,3X-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kB in macrophages", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028645A (zh) * | 2009-10-02 | 2011-04-27 | 强生消费者公司 | 包含nfkb抑制剂和非类视色素胶原促进剂的组合物 |
| CN102113978A (zh) * | 2009-10-02 | 2011-07-06 | 强生消费者公司 | 包含nfkb抑制剂和弹性蛋白原促进剂的组合物 |
| CN102113978B (zh) * | 2009-10-02 | 2014-06-25 | 强生消费者公司 | 包含nfkb抑制剂和弹性蛋白原促进剂的组合物 |
| CN102028645B (zh) * | 2009-10-02 | 2014-10-15 | 强生消费者公司 | 包含nfkb抑制剂和非类视色素胶原促进剂的组合物 |
| US9289361B2 (en) | 2009-10-02 | 2016-03-22 | Johnson & Johnson Consumer Inc. | Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter |
| US9370474B2 (en) | 2009-10-02 | 2016-06-21 | Johnson & Johnson Consumer Inc. | High-clarity aqueous concentrates of 4-hexylresorcinol |
| US9375395B2 (en) | 2009-10-02 | 2016-06-28 | Johnson & Johnson Consumer Inc. | Compositions comprising an NFκB-inhibitor and a tropoelastin promoter |
| US9629794B2 (en) | 2009-10-02 | 2017-04-25 | Johnson & Johnson Consumer Inc. | Compositions comprising an NFκB-inhibitor and a tropoelastin promoter |
| US10307352B2 (en) | 2012-09-24 | 2019-06-04 | Johnson & Johnson Consumer Inc. | Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester |
| CN107184482A (zh) * | 2017-06-26 | 2017-09-22 | 上海家化联合股份有限公司 | 马黛茶提取物及其在皮肤外用剂中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2482809A1 (en) | 2012-08-08 |
| ES2674569T3 (es) | 2018-07-02 |
| KR20120083448A (ko) | 2012-07-25 |
| US20110081433A1 (en) | 2011-04-07 |
| CA2774026A1 (en) | 2011-04-07 |
| BR112012007512A2 (pt) | 2016-11-22 |
| US8318217B2 (en) | 2012-11-27 |
| RU2012117746A (ru) | 2013-11-10 |
| WO2011041648A1 (en) | 2011-04-07 |
| IN2012DN02441A (zh) | 2015-08-21 |
| CN102573820B (zh) | 2015-11-25 |
| HK1171954A1 (zh) | 2013-04-12 |
| CA2774026C (en) | 2018-04-24 |
| RU2554766C2 (ru) | 2015-06-27 |
| EP2482809B1 (en) | 2018-06-13 |
| KR101750296B1 (ko) | 2017-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102573820B (zh) | 包含抗炎共混物的组合物 | |
| KR101773753B1 (ko) | ＮＦκＢ-억제제 및 비-레티노이드 콜라겐 촉진제를 포함하는 조성물 | |
| KR101740290B1 (ko) | ＮＦκＢ-억제제 및 트로포엘라스틴 촉진제를 포함하는 조성물 | |
| KR20130022471A (ko) | 녹차 성분을 함유하는 화장료 조성물 | |
| CN102048724A (zh) | 用于治疗皮肤的过氧化苯甲酰组合物 | |
| JPH0761915A (ja) | 皮膚外用剤 | |
| JPH0725763A (ja) | 皮膚外用剤 | |
| TWI703988B (zh) | 使用黑莓萃取物用於增進髮質之方法及組成物 | |
| JPH09227353A (ja) | 美白化粧料組成物 | |
| KR100561780B1 (ko) | 탱자 추출물을 함유하는 항자극용 화장료 조성물 | |
| JP5855949B2 (ja) | ケラチン産生促進剤、染毛用剤及びマニキュア用剤 | |
| TWI854702B (zh) | 具清除自由基功能的複方精油及其在抗氧化上的用途 | |
| JP2001072567A (ja) | 皮膚化粧料 | |
| JP2003095884A (ja) | ツルグミを用いた育毛剤原料 | |
| NZ729134A (en) | Methods and compositions for enhancing hair quality using blackberry extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1171954 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1171954 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 Termination date: 20201001 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |